South San Francisco-based clinical-stage biopharmaceutical company Alumis Inc. closed its upsized Series C funding round after securing $259 million from venture capital investors.

Venture Capital Investors

A California-based biotech company specializing in developing oral therapies for immune dysfunction and autoimmune indications, with a focus on TYK2 inhibition.

https://www.alumis.com/

Alumis Inc. raised $259M in a upsized funding round to support its clinical-stage biopharmaceutical development.

Investors

Description

Company Information

Related People

Funding Insights

Alumis Inc. raised $259M in a upsized funding round to support its clinical-stage biopharmaceutical development.

Investors

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information